Abstract: The most prevalent nucleoside reverse transcriptase inhibitor resistance mutations were M184I/V (90%), Q151M (24%), and S215F/Y (24%).
Method: In this study, HIV-2 resistance mutations were identified using the list generated by the 'Collaborative HIV and Anti-HIV Drug Resistance Network', leading to the following mu
Result: The most prevalent resistance mutations to NRTI were the following: M184V (n = 17, 81%), Q151M (n = 5, 24%), S215F/Y (n = 5, 24%), V111I (n = 4, 19%), K65R (n = 3, 14%), M184I (n = 2, 10%), and D67N (n = 2, 10%).
Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.
Discussion: Results from the HIV-1 drug resistance mutation research by the International AIDS Society-USA (updated in March 2013) have revealed that PI resistance mutation sites are L10I, K20M, V32I, M36I, M46I/L, I47V/A, I50V, Q58E, A71V, G73S, V82A/F/T, I84V, L89V,L90M; NRTIs resistance mutations are M41L, A62V, PMID: 24704709
2014
Antiviral therapy
Abstract: METHODS: In total, 15,991 samples submitted to Monogram Biosciences (South San Francisco, CA, USA) for routine resistance testing between January 2010 and June 2011 were assessed for the presence of known rilpivirine RAMs K101E/P, E138A/G/K/Q/R, V179L, Abstract: Median FC values >2.0 were observed for clinical isolates with rilpivirine RAMs K101P, E138Q/R, Y181C/I/V, Y188L or M230L, and for the combination of E138K with M184I/V, and K101E with M184I.
Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia.
Abstract: The most frequent mutations were K103N and M184VI.
Result: Combined NNRTI and NRTI mutations were seen in four of nine (44.4%) participants and involved M184V/I in all cases and K65R and D67G occurred in one participant in addition to the M184I mutation.
Discussion: In three of nine participants with HIVDR mutations at baseline, exposure to a failing regimen during 6 months was associated with the emergence of additional mutations under drug pressure, including M184V/I.
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
PMID: 24740633
2014
The Journal of infectious diseases
Result: Both FTC-resistant viruses from participants randomized to FTC/TDF were hypersusceptible to TDF and zidovudine (ZDV; M184V virus showed fold change IC50 of 0.46 and 0.36; M184I showed fold change IC50 of 0.44 and 0.22, respectively).
Result: By the next visit, plasma viremia had increased with nonsuppressive drug exposure (TFV-DP = 1.47 fmol/106 cells, FTC-TP = 0.073 pmol/106 cells) and M184I was evident by genotype.
Result: The mutation M184I remained predominant at week 15 (99.5% by qMVA, 98.1% by 454 sequencing), dropping to <0.5% by week 29, and remaining at residual levels.
Result: The participant with minor variant M184I (0.53% by qMVA, open symbols) had undetectable plasma drug levels, and low but detectable PBMC drug levels prior to SC (FTC-TP 2.62 pmol/106 cells; TFV-DP 3.58 fmol/106
Transmitted drug resistance to rilpivirine among antiretroviral-naive patients living with HIV from northern Poland.
PMID: 24746180
2014
Journal of the International AIDS Society
Result: The M184I mutation was not found in the analysed data set.
Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.
Abstract: We show here that four mutations (Y115F, M184V, M184I, and Q151M) in the dNTP-binding pocket of RT that had relatively small effects on the overall HIV-1 mutation rate (less than 3-fold compared to the wild type) significantly increased mutations at some specific positions in the lacZalpha reporter gene.
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
Result: All children were exposed to 3TC, and the majority of them (n = 316, 89.3%) harboured the M184V/I mutation (Figure 5).
Discussion: However, this finding does not significantly impact options for 2nd-line drugs, as M184V/I reduces viral fitness and often delays the development of TAMs.
Discussion: The frequency of M184V/I and consequent high-level resistance to 3TC/FTC is consistent with results found in most other South African studies.
Discussion: This M184V/I mutation also caused intermediate resistance to ABC in more than 80% of the d4T-exposed children.
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA).
Abstract: Rilpivirine (RPV) is a novel NNRTI with a mutational pattern different from first-generation drugs of the same class: 16 resistance-associated mutations (RAM) are listed, but the combination E138K + M184I seems to be the most important.
Abstract: TDF, EFV, and possibly FTC may predispose to the selection for M184I.
Abstract: The combination E138K + M184I is absent in both naive and experienced subjects.
[Analysis of HIV genotypic drug resistance among pediatric HIV/AIDS cases with virological failure after free antiretroviral therapy in Yunnan province].
Abstract: The prevalent mutations associated with drug resistance were M184V/I, K103N, T215F/Y, G190A, Y181C and K101E at the frequencies of 52.1% (38/73), 30.1% (22/73), 21.9% (16/73), 20.5% (15/73), 15.1% (11/73) and 12.3% (9/73) respectively.
HIV mutation literature information.
PMID: 
2014
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT